Grifols (XMAD:GRF) Cyclically Adjusted Revenue per Share: €9.36 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:GRF Grifols SA XMAD:GRF
82 GF Score
Price €9.13
GF Value €10.98
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Grifols Cyclically Adjusted Revenue per Share?

Grifols XMAD:GRF +1.24% 82 Cyclically Adjusted Revenue per Share is €9.36 as of Mar. 2026. GuruFocus rates XMAD:GRF with a GF Score™ of 82/100 and a GF Value™ of €10.98 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Grifols's adjusted revenue per share for the three months ended in Mar. 2026 was €2.498. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Grifols's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Grifols was 10.80% per year. The lowest was 8.80% per year. And the median was 10.20% per year.

As of today (2026-07-17), Grifols's current stock price is €9.132. Grifols's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €9.36. Grifols's Cyclically Adjusted PS Ratio of today is 0.98.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.91. And the median was 1.67.


Grifols  (XMAD:GRF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Grifols's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.132/9.36
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grifols was 6.43. The lowest was 0.91. And the median was 1.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Grifols Cyclically Adjusted Revenue per Share Related Terms


Grifols Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Grifols's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Cyclically Adjusted Revenue per Share Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 7.12 7.76 8.43 9.18

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.60 8.85 8.94 9.18 9.36

XMAD:GRF vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted PS Ratio falls into.


XMAD:GRF
82GF Score
Grifols SA XMAD:GRF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grifols's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.498/129.8600*129.8600
=2.498

Current CPI (Mar. 2026) = 129.8600.

Grifols Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.417 101.138 1.819
201509 1.386 99.559 1.808
201512 1.532 100.268 1.984
201603 1.378 98.638 1.814
201606 1.426 100.333 1.846
201609 1.483 99.737 1.931
201612 1.608 101.842 2.050
201703 1.554 100.896 2.000
201706 1.651 101.848 2.105
201709 1.510 101.524 1.931
201712 1.563 102.975 1.971
201803 1.496 102.122 1.902
201806 1.625 104.165 2.026
201809 1.685 103.818 2.108
201812 1.740 104.193 2.169
201903 1.719 103.488 2.157
201906 1.836 104.612 2.279
201909 1.921 103.905 2.401
201912 1.967 105.015 2.432
202003 1.890 103.469 2.372
202006 2.172 104.254 2.705
202009 1.967 103.521 2.467
202012 1.898 104.456 2.360
202103 1.734 104.857 2.147
202106 1.975 107.102 2.395
202112 0.000 111.298 0.000
202206 2.273 118.044 2.501
202209 2.270 117.221 2.515
202212 2.525 117.650 2.787
202306 2.615 120.278 2.823
202309 2.352 121.343 2.517
202312 2.606 121.300 2.790
202406 2.450 124.409 2.557
202409 2.638 123.121 2.782
202412 2.903 124.753 3.022
202503 2.625 125.531 2.716
202506 2.746 127.251 2.802
202509 2.741 126.840 2.806
202512 2.912 128.400 2.945
202603 2.498 129.860 2.498

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.36 mean?
Grifols (XMAD:GRF) has a Cyclically Adjusted Revenue per Share of €9.36 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grifols and its competitors.
Is Grifols' Cyclically Adjusted Revenue per Share too high?
Grifols' current Cyclically Adjusted Revenue per Share is €9.36. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Grifols' Cyclically Adjusted Revenue per Share of €9.36 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grifols and its competitors. Grifols's current Cyclically Adjusted Revenue per Share is €9.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (XMAD:GRF) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.98, compared to a current price of €9.13 — trading 16.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.36. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Grifols (XMAD:GRF), the current Cyclically Adjusted Revenue per Share is €9.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (XMAD:GRF) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of €9.13 is trading 16.8% below its estimated GF Value™ of €10.98. GuruFocus considers Grifols to be Modestly Undervalued.

Key valuation signals for XMAD:GRF:

  • Cyclically Adjusted Revenue per Share: €9.36
  • GF Value™: €10.98 vs. price of €9.13 (16.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the XMAD:GRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score

Get the complete analysis for XMAD:GRF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price
€10.98
GF Value